- In-licensed patented technology from University of New Hampshire for production of hyperpolarized xenon-129
- Filed Investigational New Drug status with the US FDA for hyperpolarized xenon-129
- Determined that drug research for regulatory advancement could proceed under FDA safe-harbor
- Completed Phase I studies of 30 healthy volunteers in 2006, advancing to Phase II
- Assembled world class development team
- Scaled up the productive output of hyperpolarized xenon-129 ten-fold
- Applied new technology to SEOP production of hyperpolarized helium-3, improving production rates ten-fold
- Raised $7M in non-dilutive capital through competitive research grant proposals
- Fifth patent awarded strengthens Xemed’s worldwide patent portfolio
- Secured collaboration with first pharmaceutical partner to evaluate imaging biomarkers for cystic fibrosis severity
- Established collaboration to evaluate MagniXene®-guided bronchial thermoplasty
- Expanding MagniXene® Imaging Network by negotiating with six new Centers for temporary and long-term installations of XeBox-E10
Xemed is a product focused diagnostic drug company with broad expertise and IP in the field of hyperpolarized gas MRI, partnering with clinical researchers, the pharmaceutical industry, and the NIH to advance pulmonary functional imaging through the regulatory approval process towards commercialization
